Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand Eli Lilly raised its outlook for the year after revenue surged in its latest quarter on continued demand for its ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.

A trial of Eli Lilly’s diabetes drug Mounjaro did not meet expectations for outperforming Trulicity in preventing heart ...

(LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better than ...